Rozrolimupab

Drug Profile

Rozrolimupab

Alternative Names: Anti-RhD; Anti-Rhesus D; Anti-rhesus D immunoglobulin Gs; Anti-rhesus D polyclonal antibodies; Sym-001; Symphoglobulin-D

Latest Information Update: 15 May 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Symphogen
  • Class Immunoglobulins; Polyclonal antibodies; Recombinant proteins
  • Mechanism of Action Rh-Hr blood group system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Haemolytic disease of newborn; Immune thrombocytopenic purpura

Most Recent Events

  • 01 May 2013 Rozrolimupab is considered to be outside Symphogen's oncology focus, and its further development is dependent on identification of a global partner
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IM)
  • 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top